Varnimcabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of adult differentiated autologous T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv), derived from the CD19-A3B1 hybridoma, linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. The autologous T cells were stimulated with anti-CD3 and anti-CD28 antibodies, expanded with interleukin (IL) 7 (IL-7) and IL-15, and transduced with a lentiviral vector containing the CAR gene construct. Upon administration, varnimcabtagene autoleucel target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

**Synonyms:** - ARI 0001 - ARI-0001 - ARI0001 - Autologous Anti-CD19 CAR T Cells ARI-0001 - Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells ARI-0001 - CD19 CAR-T Cells ARI-0001 - PEI 19-187 - VARNIMCABTAGENE AUTOLEUCEL